Biotech, Diagnostics, Drug Discovery, Immunology, Medical Device, Medicine, Nanotechnology, Therapeutics, biochemistry, cell biology, microbiology, molecular biology, antibodies, molecular diagnostics, proteins, vaccines, diagnostic devices, infectious diseases, antibodies
Dr. Bello-Gil possesses a robust scientific background aimed to identify business opportunities in Life Sciences. Daniel is a Biochemist (2003) and holds a Ph.D. in Molecular & Cell Biology (2013). Daniel is currently undertaking an MBA (2019-2021). His expertise is mainly linked to areas related to protein biotechnology, industrial microbiology, and immunology. He is an expert on the role of natural anti-glycan antibodies in the progression of infectious diseases and on xenotransplantation. His scientific career has been recognized and awarded by the European Molecular Biology Organization, EMBO (2008); the International Union of Biochemistry and Molecular Biology, IUBMB (2006), and The Swiss Government Excellence Scholarships (2006). Dr. Bello-Gil holds two patents. He is the author of several peer-reviewed scientific publications. Daniel has participated in local, regional, and European scientific projects, performing not only research activities but also scientific management, with personnel under his direct supervision both in academia and clinical environment. In 2016, Daniel began a freelance consultant career, basically doing scientific due diligence for Biotech companies of Catalunya to primary scientific projects from academia. His interest in business and entrepreneurship grew, and as a result, he founded RemAb Therapeutics in 2018. Currently, he is the Chief Scientific Officer (CSO) of RemAb Therapeutics.